Objectives: To investigate the potential synergy of IL-7-driven T cell-dependent and TLR7-mediated B cell activation and to assess the additive effects of monocyte/macrophages in this respect.
Introduction
Interleukin-7 (IL-7) is a potent T cell activating cytokine that causes proliferation, survival and differentiation of T cells in the periphery to maintain homeostatic T cell balance [1] . Not only in health, but also in disease, IL-7 has been shown to play an important role in T cell expansion and enhancement of T celldriven immunity. Addition of IL-7 increases T cell numbers and functionality in immunodeficient states due to HIV infection, chemotherapy, and after bone marrow transplantation [2, 3, 4] .
Furthermore, IL-7 and its receptor have been implicated in several autoimmune diseases like rheumatoid arthritis (RA) [5, 6, 7] , psoriasis [8] , spondylarthritis [9] , inflammatory bowel's disease (IBD) [10, 11] multiple sclerosis (MS) [12, 13, 14] , and recently primary Sjögren's Syndrome (pSS) [15, 16] . In the inflamed tissues of patients with autoimmune diseases, increased IL-7 production and IL-7 receptor (IL-7R) expression by tissue cells and immune cells have been documented [5, 6, 7, 8, 9, 15, 16] . In many in vitro models IL-7 was shown to induce T cell activation (Th1 and Th17 induction) and T cell-dependent activation of monocytes/macrophages and dendritic cells (DCs) [5, 15, 17] . In addition, gene polymorphisms of the IL-7Ra gene are associated with susceptibility to MS [13] . Finally, IL-7 and IL-7R have been shown to play critical proinflammatory roles in experimental models for diabetes, MS, IBD and RA [3, 14, 18, 19, 20] .
Although its role on T cell activation has extensively been studied (reviewed in [21, 22] ), less is known about the stimulatory effect of IL-7 on B cells. Although reduced serum immunoglobulin levels in IL-7R-deficient individuals suggested that IL-7 might play a role in activation of mature human B cells [23] , direct evidence for this is lacking. Recently, we found that, at least in vitro, IL-7 significantly and equally effective increased B cell activation in PBMC culture and CD4 T cell co-culture of healthy controls and patients with pSS [24] . Another recently published study demonstrated that IL-7 modulates survival and activation of B cells from healthy controls trough CD70 expression by T cells [25] . In the present study it was investigated to what extent IL-7-driven T cell-dependent B cell activation could synergize with TLR7-driven B cell activation.
Pathogen-associated molecular pattern (PAMP) -recognizing molecules such as Toll-like receptors (TLRs) have extensively been examined and have been implicated to play an important role in autoimmune diseases like RA [26, 27] , systemic sclerosis [28] , systemic lupus erythematosus (SLE) [29] , and pSS [30, 31, 32, 33] . Because of the predominance of autoantibodies directed against RNA-binding proteins (anti-Ro and La), in several systemic autoimmune diseases TLR7 has been studied. TLR7 is located intracellular, in the endosomal compartments of B cells and plasmacytoid DCs (pDCs) [34, 35] . TLR7 is specialized in recognizing single-stranded RNA (ssRNA) originating from viruses [34] , but it has been postulated that self-RNA becomes a target, when self-tolerance is breached [36] . This break of tolerance has been demonstrated upon EBV infection, inducing anti-Ro and Sm antibodies [37, 38] . In autoimmune diseases, autoantibodies directed against RNA-binding self-antigens (anti-Ro/SSA and La/SSB), consequently deliver aberrantly exposed extracellular RNA to the endosomal compartment of B cells and pDCs (via the B cell receptor or Fc receptors) and subsequently trigger TLR7 signalling [39] .
TLR7 and IL-7 (eg. upon viral triggering) could be involved in the early stages of B cell immunopathology of several systemic autoimmune diseases, this study aimed to investigate the hypothesis of synergistic B and T cell activation upon TLR7-driven B cell and IL-7-driven T cell stimulation. In addition, increased numbers of monocytes/macrophages are present at sites of inflammation and activated monocytes (eg. with enhanced IFN signature) are present in the circulation of systemic autoimmune diseases [40, 41] . Given the importance of myeloid cells in immunopathology of many rheumatic diseases like RA, the capacity of monocytes/macrophages to potentiate this effect was examined to reveal their potential contribution to TLR7/IL-7-driven immune activation in systemic autoimmune diseases. In this respect the ratio of T and B cells and monocytes/macrophages (1:1:0,1) used in this study was chosen similar to that observed at sites of inflammation, such as in the labial salivary gland of pSS patients.
Methods

Ethics Statement
Peripheral blood from healthy donors was used in this study. They have given a written consent to participate in the in-house donor program, approved by the UMCU medical ethical committee. This study has been approved by the UMCU medical ethical committee.
Cell isolation and culture
Peripheral blood (PB) from healthy donors was diluted 1:1 with RPMI 1640 medium (Gibco BRL, Life Technologies, Belgium) containing penicillin (100 U/ml), streptomycin (100 mg/ml) and glutamine (2 mM) (PSG). Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation using FicollPaque (Pharmacia, Uppsala, Sweden). CD19 B cells, CD14 monocytes/macrophages and CD4 T cells were isolated from PBMCs by magnetic-activated cell sorting (MACS). CD19 cells and CD14 monocytes/macrophages were positively selected by incubating PBMCs with anti-CD19 or anti-CD14 labelled with goat anti-mouse IgG magnetic beads (Miltenyi Biotec, Utrecht, The Netherlands) following MACS procedures according to manufactures instructions using the autoMACS (Miltenyi Biotec). Untouched CD4 T cells were negatively selected by using the CD4 isolation kit II (Miltenyi Biotec) and autoMACS (Miltenyi Biotec).
CD4 T cells and CD19 B cells were co-cultured 1:1 in 96-wells plates and proliferation determined by 3 H-thymidine incorporation during the last 18 hours of culture (5 mCi/ml, NEN Life Science Products, Amsterdam, The Netherlands). Additionally, proliferation and activation of B and T cells was determined by surface activation marker expression and intracellular Ki67 expression, respectively (24-wells plate). Cells were cultured for 4 days at a concentration of 5.10 5 cells/ml at 37uC. For analysis of cytokine and immunoglobulin levels, after a 62 and 122days culture period respectively, supernatants were rendered cell free and stored at -80uC until analysis. In addition, all analyses were also performed for CD4 T/CD19 B cell co-cultures in the presence of CD14 monocytes/macrophages (5.10 4 cells/ml, 1:1:0,1 ratio). Cells were cultured in RPMI/glutamax (Gibco BRL) with additional penicillin (100 U/ml, Yamanouchi), streptomycin (100 mg/ml Fisiopharma), and 10% fetal calf serum (FCS, Gibco BRL) in the presence or absence of 1 ng/ml TLR7 agonist (Gardiquimod, Invivogen, San Diego, CA, USA) and 10 ng/ml IL-7 (Peprotech Inc., Rocky Hill, NY, USA). An increase in proliferation and activation/maturation is regarded as additive when the combination of stimulations is the sum, and synergistic when the combination of stimulations is higher than the sum of the individual stimulations (minus the value of the unstimulated control condition).
Markers of activation, proliferation, and B cell differentiation by flow cytometry
Expression of the following markers on CD4 T cells and CD19 B cells was assessed after 4 days in culture using the following monoclonal antibodies (mAb): CD4-PerCP (Biolegend, San Diego, CA, USA), CD19-APC (BD, Erembodegem-Aalst, Belgium), CD25-PE (DAKO, Glostrup, Denmark), and HLA-DR-FITC (BD). For analysis of B cell differentiation the following monoclonal antibodies were used: CD3-FITC (BD Pharmingen, San Diego, CA, USA), CD19-APC-Alexa Fluor750 (BD), CD20-eFluor450 (eBioscience, San Diego, CA, USA) CD27-APC (ImmunoTools GmbH, Friesoythe, Germany), CD38-PE-CY7 (BD), and IgD-PE (BD). IgG1-FITC/IgG1-PE (Immunotech, Marseille, France) was used as isotype control.
Ki67 intracellular staining was performed using mouse-antihuman Ki67-FITC staining set (eBioscience) following manufactures instructions. Cell acquisition was done using a FACScan flow cytometer and data were analysed with FlowJo software, version 7.5 (Tree Star Inc., Oregon, USA).
Immunoglobulin and cytokine measurements
IgG, IgM were measured by ELISA according to the manufacturer's instructions (Bethyl laboratories, Montgomery, TX, USA), kappa and lambda free light chains (FLCs) were measured with in-house developed ELISA kits adapted from Abe et al. [42] , and described elsewhere [43] . IL-6 levels were determined by ELISA according to the manufacturer's instructions (Biosource, Etten-Leur, The Netherlands; detection limit 10 pg/ml). All other cytokines (IFNc, IL-2, IL-4, IL-10, IL-17A, IL-21, IL-22) were determined by a multiplex cytokine assay as extensively described elsewhere [44] .
Statistical analysis
Culture conditions were analysed by the parametric paired sample t test or the nonparametric Wilcoxon's singed rank test where appropriate. All statistical analyses were performed using Graphpad Prism (GraphPad Prism 5.0, GraphPad software Inc.) and differences with a p-value of 0.05 or less were considered statistically significant. TLR7 specifically induced B cell activation, as measured by KI67 + (from 1.2 60.2% to 9.3 61.4%, p,0.01). Whereas IL-7 on its own only slightly increased B cell proliferation (from 1.2 60.2% to 3.7 60.7%, p,0.05), the combination of IL-7 and TLR7 synergistically increased the number of Ki67 + B cells (33.4 67.3%) ( fig. 1C) . Furthermore, TLR7-induced B cell proliferation (30.2 68.9%, p = 0.07) and TLR7/IL-7-induced stimulation (63.0 68.0%, p,0.01) ( fig. 1D ) was enhanced by monocytes/macrophages. The average cell viability for these cell cultures was 75.4 62.4% for the unstimulated, 76.9 63.1% for TLR7-stimulated, 77.3 61.3% for IL-7-stimulated and 77.0 62.9% for IL-7/TLR7-stimulated cultures in the absence of monocytes/macrophages (n = 8). In the presence of monocytes/macrophages the average cell viability was 82.3 61.8% for the unstimulated, 76.4 62.5% for TLR7-stimulated, 79.7 62.1% for IL-7-stimulated and 76.6 62.7% for IL-7/TLR7-stimulated cultures (n = 8). No statistically 
Results
TLR7 and IL-7 synergistically increase proliferation of B cells in co-culture with CD4 T cells
TLR7 and IL-7 synergistically increase CD4 T cell proliferation in co-cultures of T cells and B cells
TLR7-induced B cell activation in CD4 T/B cell co-cultures was not associated with T cell activation (mean 6SEM; from 0.8 60.1% to 1.1 60.3%), whereas IL-7 significantly increased CD4 T cell proliferation (from 0.8 60.1% to 11.5 62.8%, p,0.05), and IL-7 added to TLR7 also synergistically increased T cell proliferation (29.2 65.2%, p,0.05) ( fig. 2A, representative;  fig. 2B , average). Monocytes/macrophages strongly enhanced proliferation of CD4 T cells upon IL-7 stimulation (from 11.5 62.8% to 49.3 62.2%, p,0.001), equally effective to the combination of IL-7 and TLR7 stimulation (51.4 66.3%) ( fig. 2C, representative; fig. 2D , average).
IL-7 additively up-regulate expression of CD19 and HLA-DR on B cells
Associated with increased B cell proliferation upon IL-7 and TLR7 stimulation, similar increases were observed for the expression of maturation and activation markers on B cells (CD19, HLA-DR, and CD25) and on T cells (HLA-DR, and CD25) ( fig. 3A, 
TLR7/IL-7-increased release of IgG, IgM, and kappa freelight chains from B cells is dependent on monocytes/ macrophages
To further evaluate the additive effect of TLR7 and IL-7 on B cells, CD4 T cells and B cells were cultured for 12 days in the presence and absence of monocytes/macrophages after which the secretion of IgG, IgM ( fig. 4A, C ) and kappa and lambda FLCs ( fig. 4B, D) ml) (all p,0.05). Again, this was not observed upon TLR7 stimulation. IL-7 and TLR7 together enhanced the increase in IgG (346.1 6170.6 ng/ml), IgM (202.3 6109.9 ng/ml), and kappa FLC secretion (397.4 6227.7 ng/ml), after 12 days of culture (all p,0.05) ( fig. 4A and B) .
The combination of TLR7 and IL-7 additively increase IL-17A and synergistically increase IFNc, IL-10 and IL-22 secretion
Next it was assessed whether stimulation of immunoglobulin was associated with increased expression of activation markers on CD4 T cells ( fig. 5A) or cytokine production (fig. 5B, C) . The percentages of activated HLA-DR-expressing T cells were 5A ). Upon addition of monocytes/macrophages to the T/B cell cultures, the overall HLA-DR expression increased slightly and a significant (both p,0.05) additive effect of the combination vs. TLR7 and IL-7 monocultures was now seen (IL-7, TLR7 vs. IL-7/TLR7; 16.3 62.8%, 17.7 62.9% vs. 20.4 63.1%, fig. 5A ).
To see whether the additive activation of B cells is associated by specific T helper cell activity major T cell-related cytokines; IFNc, IL-2 (Th1), IL-17A, IL-21 and IL-22 (Th17), and IL-4 (Th2), were measured in supernatants of the co-cultures. In T/B co-cultures IL-4, IL-2 and IL-21 were not detected by Luminex assay, however a slight, but statistically significant increase was seen for IFNc, IL-17A and IL-22 upon IL-7/TLR7 stimulation. In the presence of monocytes/macrophages a markedly elevated increase was seen upon TLR7 stimulation for IFNc, IL-17A and IL-22 (med vs. TLR7A; IFNc, 0.1 60 vs. 112 682 pg/ml; IL-17A, 9.8 62.7 vs. 182 6142 pg/ml; IL-22, 5.5 63.1 vs. 146 692 pg/ml, all p,0.05) and IL-7 stimulation for IL-17A and IL-22 (med vs. IL-7; IL-17A, 9.8 62.7 vs. 145 677 pg/ml; IL-22, 5.5 63.1 vs. 78.7 645 pg/ml, both p,0.05). Furthermore, an additive TLR7/IL-7-induced increase was observed for the release of IL-17A (417 6226 pg/ml, p,0.05), while IFNc (548 6236 pg/ml, p,0.05) and IL-22 (1284 6721 pg/ml, p,0.01), were synergistically increased ( fig. 5B ).
Cytokines that are released both by B cells and monocytes/ macrophages and have the potential to stimulate B cells were measured as well. IL-10 also showed a significant increase upon TLR7 stimulation in CD4 T cell/B cell co-culture without (med vs. TLR7A; 0.1 60 vs. 31 627 pg/ml, p,0.05) and with monocytes/ macrophages (med vs. TLR7A; 1.7 60.7 vs. 159 659 pg/ml, p,0.05), which was synergistically increased upon the addition of IL-7, both in the absence (155 6118 pg/ml, p,0.05) and presence (482 6155 pg/ml, p,0.01) of monocytes/macrophages. IL-6 was potently increased by TLR7 stimulation (102 649 pg/ ml, p,0.01) independently of IL-7 (110 655 pg/ml, ns), and showed a 10-fold increase (1126 6505 pg/ml, p,0.01) when monocytes/macrophages were present ( fig. 5C ).
Discussion
Here we report the synergistic effect of IL-7 and TLR7 on the proliferation and activation of both CD19 B and CD4 T cells. Furthermore, it is demonstrated that synergistic increases in immunoglobulin production are associated with synergistic induction of Th1-and Th17-related cytokines and are critically dependent on monocytes/macrophages.
Others and we have demonstrated increased numbers of Ki67-expressing proliferating lymphocytes at sites of inflammation [24, 45, 46] . In salivary glands of patients with pSS we have shown that Ki67 expression is associated with IL-7 expression [24] . In this study it is demonstrated that in co-cultures of T and B cells, IL-7 causes a profound increase in Ki67-expressing proliferating CD4 T cells, and a modest, but significant B cell proliferation. Additionally, the present data show that TLR7 stimulates B cell proliferation at a higher level, but most important IL-7 and TLR7 synergistically increases (Ki67 + ) proliferating B cells and T cells. Previously, increased expression of TLR7 in patients with pSS has also been found [47] . This suggests that both stimuli at inflammatory sites of patients with pSS, but also in other diseases, can strongly contribute to T cell and B cell proliferation.
To our knowledge the present data are also the first to demonstrate that in the presence of monocytes/macrophages IL-7-driven T cell activation and TLR7-driven B cell activation synergistically induce immunoglobulin secretion, in the absence of B cell receptor cross-linking. Cooperation of TLRs with other inflammatory mediators in the activation of B cells has been reported before, but this has mostly been in combination with BCR triggering [39, 48, 49, 50] . Overall, stimulation of the BCR together with TLRs significantly enhances B cell effector functions. The co-engagement of TLR7 and BCR has been shown to promote autoreactive B cell activity [51, 52] indicating that this could contribute to disease symptoms in autoimmune diseases. Others have shown that TLR7 can also cooperate with CD40 to enhance IL-6 secretion, independently of BCR signals [53] . However, in this latter study it has not been shown that this leads to immunoglobulin secretion. The culture system used in this study also demonstrates that in an antigen-independent environment locally overexpressed IL-7 and TLR7 [8, 16, 47] , as has been shown in several autoimmune diseases, are sufficient to trigger immunoglobulin production, which makes this a relevant observation.
In association with synergistic B cell activation IL-7 and TLR7 synergistically induce Th1 and Th17 activity, which is also critically dependent on monocytes/macrophages. Surprisingly, although TLR7 hardly induces proliferation of CD4 T cells, even in the presence of monocytes/macrophages, TLR7 stimulation by itself already induced IFNc, IL-17A and IL-22 secretion. Our data corroborate recent findings demonstrating that supernatants from TLR7-stimulated PBMC preferentially induce polarization of naive CD4 T cells towards the Th17 lineage and the release of Th17-related cytokines [54] . In addition, previously, we have shown that IL-7 strongly induces Th1, Th17 and to a lesser extent Th2 activity in co-cultures of CD4 T cells and monocytes/ macrophages [6, 16, 55, 56] . In the present study, T cell cytokine secretion upon IL-7 was hardly detectable, because IL-7 secretion was not measured upon mitogenic restimulation with ionomycin/ PMA or anti-CD3/CD28, as was done in our previous study and in the majority of other studies. Interestingly in this respect, without T cell restimulation, TLR7 activation together with IL-7 robustly increased expression of IFNc, IL-17 and IL-22. In contrast to the increased induction of Th12 and Th17/Th22-related cytokines, Th2-related cytokines (IL-4) were undetectable. Although in the present study the relative contribution of these T cell cytokines to B cell activation, in particular immunoglobulin secretion, was not demonstrated, previous studies have demonstrated the capacity of Th1, Th17/Th22 cells and their cytokines to cause B cell activation including immunoglobulin secretion. As indicated our data clearly show that the release of immunoglobulins by B cells and the production of T cell cytokines is critically dependent on CD14 monocytes/macrophages. In particular in the presence of combined IL-7 and TLR7 stimulation, the synergistic secretion of IgG and T cell cytokines was facilitated by monocytes/macrophages. Even in small numbers, like at the ratio we used in our cultures (T/B/mono; 1:1:0.1), monocytes/macrophages can make a distinct difference. Since monocytes themselves are hardly activated by TLR7 stimulation and they do not express the TLR7 (data not shown), effects of TLR7-activated B cells and IL-7-activated CD4 T cells could potently activate monocytes indirectly, and they in their turn can cause additional activation of B cells and T cells. Although our data do not reveal the monocyte/macrophage-driven mechanisms that are mediating the synergy of IL-7 and TLR7, they do suggest that myeloid cells, present at the site of inflammation contribute to this type of activation. In this respect, increased numbers of CD14-expressing monocytes, CD68 or CD163-expressing macrophages, CD1c or CD11c-expressing myeloid dendritic cells have been documented in different autoimmune diseases [16, 40, 45, 57, 58, 59 ]. The potency of these different subsets, as well as that of other potentiating cells such as plasmacytoid dendritic cells, which vastly express TLR7, remains to be demonstrated.
Elevated levels of IL-7 have been found in autoimmune diseases, like pSS [16] , RA [5] , JIA [60] , psoriatic arthritis [8] and MS [14] . Similarly, TLRs have been linked to the pathogenesis of autoimmune disorders and increased expression of TLRs at the site of inflammation has been documented [26, 27, 28] . The results presented in this study show that combined stimulation of B cells with TLR7 agonist and IL-7-induced T cell activation synergistically enhance proliferation of B cells and CD4 T cells. This is associated with synergistically induced secretion of T helper cytokines and immunoglobulins, which are critically dependent on monocytes/macrophages. These data provide more insight into the activation and interplay of B cells and CD4 T cells and help to understand the mechanisms that play a detrimental role in autoimmune disease.
